Celyad (CYAD) & Its Rivals Head to Head Analysis

Celyad (NASDAQ: CYAD) is one of 485 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Celyad to related businesses based on the strength of its risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.


How to Become a New Pot Stock Millionaire

This table compares Celyad and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celyad N/A N/A N/A
Celyad Competitors -3,093.91% -156.11% -27.25%

Institutional and Insider Ownership

4.7% of Celyad shares are held by institutional investors. Comparatively, 47.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.2% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Celyad has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Celyad’s competitors have a beta of 1.08, indicating that their average stock price is 8% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Celyad and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celyad 0 0 1 0 3.00
Celyad Competitors 2760 8506 21323 569 2.59

Celyad currently has a consensus target price of $74.00, indicating a potential upside of 134.92%. As a group, “Pharmaceutical preparations” companies have a potential upside of 43.46%. Given Celyad’s stronger consensus rating and higher possible upside, analysts clearly believe Celyad is more favorable than its competitors.

Valuation & Earnings

This table compares Celyad and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Celyad $4.00 million -$63.74 million -8.90
Celyad Competitors $2.03 billion $132.98 million -3.49

Celyad’s competitors have higher revenue and earnings than Celyad. Celyad is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


Celyad beats its competitors on 7 of the 13 factors compared.

Celyad Company Profile

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.

Receive News & Ratings for Celyad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply